Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in /home/stockstowatch/public_html/wp-content/mu-plugins/GrULw0.php on line 4

Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in /home/stockstowatch/public_html/wp-content/mu-plugins/GrULw0.php on line 4
Pfizer/BioNTech Seek Expanded Approval For Its Updated COVID-19 Shot As Primary Series Vaccination – Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX) – Stocks to Watch
  • Fri. May 17th, 2024

Pfizer/BioNTech Seek Expanded Approval For Its Updated COVID-19 Shot As Primary Series Vaccination – Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX)

ByVandana Singh

Feb 24, 2023
Pfizer/BioNTech Seek Expanded Approval For Its Updated COVID-19 Shot As Primary Series Vaccination - Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX)

[ad_1]

  • Pfizer Inc PFE and BioNTech SE BNTX have submitted an FDA supplemental marketing application for approval of omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as a primary series and booster dose(s) for 12 years and older.
  • In January, the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted to harmonize the composition of COVID-19 vaccines across booster and primary series doses. 
  • If this supplemental application is approved, people 12 or older can receive the companies’ omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for their primary series rather than completing their primary series with the original before having access to the bivalent vaccine. 
  • Related: Pfizer/BioNTech Get Ready For London Court Battle With Moderna Over COVID-19 Vaccine Patents.
  • The submission is supported by clinical, pre-clinical, and manufacturing data demonstrating the bivalent vaccine’s safety, tolerability, and immunogenicity. 
  • Among study participants over 55, the bivalent vaccine met the criteria for superiority over the original vaccine for Omicron BA.4/BA.5-neutralizing antibodies elicited. The safety and tolerability profile of the bivalent vaccine remained similar to that of the original vaccine. 
  • Compared to the original vaccine, the bivalent vaccine also induced a more robust neutralizing antibody response against newer Omicron sublineages in participants 55 and older. 
  • For XBB.1, neutralizing antibody titers increased 4.8-fold following a booster dose of the companies’ bivalent vaccine and 1.5-fold following a booster dose of the companies’ original vaccine.
  • Price Action: PFE shares are down 1.61% at $41.62, and BNTX shares are down 2.65% at $130.83 on the last check Friday.

[ad_2]

Image and article originally from www.benzinga.com. Read the original article here.

You missed


Notice: Function WP_Object_Cache::add was called incorrectly. Cache key must not be an empty string. Please see Debugging in WordPress for more information. (This message was added in version 6.1.0.) in /home/stockstowatch/public_html/wp-includes/functions.php on line 5835